and amortization, were $5.3 million for the quarter ended December 2007
as compared to $3.7 million for the quarter ended September 2007.
Increases this quarter were attributable to higher costs related to the
addition of the DYHP acquisition in October 2007 in addition to
additional legal and accounting costs and other business expansion such
as rents, payrolls and related insurances.
-- Research and development ("R&D") expenditures for the three months
ended December 31, 2007 totaled approximately $310,000 all of which was
charged as an expense to operations as compared to $336,000 of R&D
expense for September 2007.
CONFERENCE CALL INFORMATION
GeoPharma will host a conference call to discuss results on Thursday, February 14, 2008 at 11:30 (ET) with CEO, Mihir Taneja and VP/CFO, Carol Dore-Falcone. Interested parties may participate in the conference call by dialing 1-888-680-0869 and entering pass code 78555682, 5 minutes prior to the initiation of the call. A replay of the conference call will be available from 1:30 PM (ET) on February 14 through February 21, by dialing 1-888-286-8010 and entering pass code 37538422.
Webcast registration (http://phx.corporate- ir.net/phoenix.zhtml?c=120778&p=IROL-Guestbook&UniqueId=1754335&mp=irol- eventDetails&mpdp=EventId~1754335!WebCastId~724916!StreamId~1051110&pp=IROL - BasicWebCast&ppdp=EventId~1754335!WebCastId~724916!StreamId~1051110&pph=339 &pp w=270&rdu)
ABOUT GEOPHARMA, INC.:
GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a
diversified business model participating in 3 main market segments:
Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma
division specializes in the formulation of generic drugs for human and
veterinary usage and the development of medical devices used
|SOURCE GeoPharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved